Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 3053-3059

  Miret, C ^a   Font, J ^a   Molina, R ^a   Garcia Carrasco, M ^a   Filella, X ^a   Ramos, M ^a   Cervera, R ^a   Ballesta, A ^a   Ingelmo, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Apoptosis; Bcl 2; Cytokines; Fas; Systemic lupus erythematosus

Indexed keywords

CYTOKINE; FAS ANTIGEN; INTERLEUKIN 10; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, BCL-2; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035172034     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Should the clinician have interest in the deregulation of apoptosis in autoimmunity?
2. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: A review
3. The apoptosis/Fas protein in human systemic lupus erythematosus
4. Apoptosis and expression of soluble Fas mRNA in systemic lupus erythematosus
5. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes
6. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulation in human peripheral blood
7. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
8. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
9. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus
10. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
11. Elevated soluble Fas production in SLE correlates with HLA status not with disease activity
12. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse
13. Lymphocyte apoptosis in systemic lupus erythematosus: Relationships with Fas expression, serum soluble Fas and disease activity
14. Do elevated levels of serumsoluble Fas contribute to de persistence of activated lymphocytes in systemic lupus erythematosus?
15. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus
16. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis
17. Lack of correlation between serum soluble Fas/apo-1 levels and autoimmune diseases
18. Elimination of self-reactive lymphocytes-B proceeds in 2 stages: Arrested development and cell death
19. High levels of bcl-2 protein in circulating T lymphocytes, ut not B lymphocytes, of patients with systemic lupus erythematosus
20. Increased expression of bcl-2 protein in peripheral B cells of patients with systemic lupus erythematosus
21. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus
22. Transcriptional overexpression of the protooncogene bcl-2 in patients with systemic lupus erythematosus
23. "In vitro" apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases
24. Increased rate of apoptosis and decreased expression of bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus
25. Bcl-2 expression is unaltered in unfractionated peripheral blood mononuclear cells in patients with systemic lupus erythematosus
26. Induction of apoptosis and cytokine gene expression in T-cell lines by sera of patients with systemic lupus erythematosus
27. Systemic autoimmune disease as a consequence of defective lymphocyte death
28. Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients
29. Apoptosis in rheumatoid arthritis synovium
30. Interferon-alfa upregulates bcl-2 expression and protects B-CLL from apoptosis in vitro and in vivo
31. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression
32. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells
33. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus
34. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95)
35. Induction of apoptosis in mature T-cells by tumor necrosis factor
36. Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection
37. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: Role of decreased intracellular alfa1-TNF
38. Elevated serum interleukin-15 levels in systemic lupus erythematosus
39. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand
40. The 1982 revised criteria for classification of SLE
41. Derivation of the SLEDAI. A disease activity index for lupus patients
42. Evaluation of the bcl-2 gene locus as a susceptibility locus linked to the clinical expression of systemic lupus erythematosus
43. Role of interleukin-10 in the B-lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
44. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice
45. The role of IL-10 in human B cell activation, proliferation and differentiation
46. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD-40-activated naive B lymphocytes